ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Sexual dysfunction in multiple sclerosis: the role of orexin-A and calpain-2 - a pilot study.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSexual dysfunction (SD) is a common autonomic symptom in patients with multiple sclerosis (pwMS), significantly affecting their quality of life. Alterations in serum levels of calpain-2 (CAPN2) and orexin-A (ORX-A) may contribute to SD development.
objectiveThis study aimed to assess the prevalence of SD in pwMS and investigate its association with serum CAPN2 and ORX-A levels.
methodsFifty-seven pwMS diagnosed with relapsing-remitting MS were enrolled. Participants completed the Arizona Sexual Experiences Scale (ASEX), Multiple Sclerosis Quality of Life-54 (MSQoL-54), Beck Depression Inventory (BDI), and Composite Autonomic Symptom Score-31 (COMPASS-31). Serum CAPN2 and ORX-A levels were measured by enzyme-linked immunosorbent assay (ELISA).
resultsSD prevalence was 50.9%. Age, gender, depression status, and serum ORX-A levels were significant predictors of SD. Serum ORX-A levels were significantly lower in pwMS with SD, while CAPN2 levels did not differ. Depression scores correlated moderately with autonomic dysfunction scores. Spinal cord lesions were not significantly associated with SD.
conclusionMultiple factors contribute to sexual dysfunction in pwMS. While serum calpain-2 levels did not show a significant association with SD in this study, reduced serum orexin-A levels appear to play a key role in its pathogenesis. Further research is needed to clarify the role of calpain-2 and other molecular mechanisms. Identification of biological markers such as orexin-A may improve management strategies for SD in MS.
Indexed as
Identifiers
41615500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.